Login to Your Account



Financings Roundup

Enanta Raises $56M in IPO; Soars on First Day Trading

By Jennifer Boggs
Managing Editor

Friday, March 22, 2013
Hepatitis C virus (HCV) player Enanta Pharmaceuticals Inc. priced a $56 million initial public offering (IPO) and received a warm welcome from Wall Street, as its newly listed shares shot up 22.7 percent on its first day of trading.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription